Interactions of mutant p53 with DNA: Guilt by association

Oncogene

Volumn 26, Issue 15, 2007, Pages 2185-2190

  Kim, E ^a   Deppert, W ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

Chromatin interaction; DNA binding; Mutant p53; Non B DNA; Transcription

Indexed keywords

DNA; MUTANT PROTEIN; PROTEIN P53;

AMINO ACID SEQUENCE; BINDING KINETICS; CARCINOGENESIS; CELL CYCLE REGULATION; CHROMATIN; DNA BINDING MOTIF; DNA DAMAGE; GENE LOCUS; GENETIC TRANSCRIPTION; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

DNA; HUMANS; MUTATION; NEOPLASMS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34047223509     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210312     Document Type: Review

References (49)

1. Ahn J, Prives C. (2001). The C-terminus of p53: the more you learn the less you know. Nat Struct Biol 8: 730-732.
2. Ang HC, Joerger AC, Mayer S, Fersht AR. (2006). Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem 281: 21934-21941.
3. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y et al. (2005). p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47: 29-41.
4. Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B et al. (2001). p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20: 3573-3579.
5. Chicas A, Molina P, Bargonetti J. (2000). Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun 279: 383-390.
6. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355.
7. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. (2006). Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191-202.
8. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. (1992). Definition of a consensus binding site for p53. Nat Genet 1: 45-49.
9. Feng Z, Jin S, Zupnick A, Hoh J, de Stanchina E, Lowe S et al. (2006). p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25: 1-7.
10. Frazier MW, He XP, Wang JL, Gu ZM, Cleveland JL, Zambetti GP. (1998). Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 18: 3735-3743.
11. Gilliland DG. (2001). The diverse role of the ETS family of transcription factors in cancer. Clin Cancer Res 7: 451-453.
12. Go¨hler T, Jager S, Warnecke G, Yasuda H, Kim E, Deppert W. (2005). Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 33: 1087-1100.
13. Go¨hler T, Reimann M, Cherny D, Walter K, Warnecke G, Kim E et al. (2002). Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain. J Biol Chem 277: 41192-41203.
14. Gu L, Zhu N, Findley HW, Woods WG, Zhou M. (2004). Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively. J Biol Chem 279: 52141-52149.
15. Gu Z, Kuntz-Simon G, Rommelaere J, Cornelis J. (1999). Oncogenic transformation-dependent expression of a transcription factor NF-Y subunit. Mol Carcinog 24: 294-299.
16. Gualberto A, Hixon ML, Finco TS, Perkins ND, Nabel GJ, Baldwin Jr AS. (1995). A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. Mol Cell Biol 15: 3450-3459.
17. Hupp TR, Lane DP. (1994). Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symp Quant Biol 59: 195-206.
18. Imbriano C, Gurtner A, Cocchiarella F, Di Agostino S, Basile V, Gostissa M et al. (2005). Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol 25: 3737-3751.
19. Inga A, Monti P, Fronza G, Darden T, Resnick MA. (2001). p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20: 501-513.
20. Joerger AC, Fersht AR. (2007). Structure - function - rescue: the diverse nature of common p53 cancer mutants. Oncogene doi:10.1038/sj.onc. 1210312.
21. Joerger AC, Ang HC, Fersht AR. (2006). Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103: 15056-15061.
22. Kim E, Deppert W. (2003). The complex interactions of p53 with target DNA: we learn as we go. Biochem Cell Biol 81: 141-150.
23. Kim E, Deppert W. (2004). Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem 93: 878-886.
24. Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, Nusing RM et al. (2003). Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 22: 7716-7727.
25. Koga H, Deppert W. (2000). Identification of genomic dna sequences bound by mutant p53 protein (Gly245->Ser) in vivo. Oncogene 19: 4178-4183.
26. Koutsodontis G, Vasilaki E, Chou WC, Papakosta P, Kardassis D. (2005). Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J 389: 443-455.
27. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. (2001). Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410: 116-120.
28. Menendez D, Inga A, Jordan A, Resnick MA. (2007). Changing the p53 master regulatory network: ELEMENTary, my dear Mr.Watson. Oncogene (this issue).
29. Mu¨ller BF, Paulsen D, Deppert W. (1996). Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene 12: 1941-1952.
30. Nguyen TT, Cho K, Stratton SA, Barton MC. (2005). Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene. Mol Cell Biol 25: 2147-2157.
31. Oikawa T. (2004). ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95: 626-633.
32. Okorokov AL, Sherman MB, Plisson C, Grinkevich V, Sigmundsson K, Selivanova G et al. (2006). The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J 25: 5191-5200.
33. Pang JH, Good LF, Chen KY. (1996). The age-dependent binding of CBP/tk, a CCAAT binding protein, is deregulated in transformed and immortalized mammalian cells but absent in premature aging cells. Exp Gerontol 31: 97-109.
34. Pastorcic M, Das HK. (2000). Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene. J Biol Chem 275: 34938-34945.
35. Sampath J, Sun DX, Kidd VJ, Grenet J, Gandhi A, Shapiro LH et al. (2001). Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276: 39359-39367.
36. Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R. (2003). DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422: 909-913.
37. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF et al. (2005). Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25: 10097-10110.
38. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF et al. (2004). Modulation of gene expression by tumor-derived p53 mutants. Cancer Res 64: 7447-7454.
39. Selivanova G, Iotsova V, Okan I, Fritsche M, Stroem M, Groner B et al. (1997). Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 3: 632-638.
40. Sigal A, Rotter V. (2000). Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 60: 6788-6793.
41. Sinden RR, Potaman VN, Oussatcheva EA, Pearson CE, Lyubchenko YL, Shlyakhtenko LS. (2002). Triplet repeat DNA structures and human genetic disease: dynamic mutations from dynamic DNA. J Biosci 27: 53-65.
42. Stenger EJ, Tegtmeyer P, Mayr GA, Reed M, Wang Y, Wang P et al. (1994). p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J 13: 6011-6020.
43. Strano S, Dell'Orso S, DiAgostino S, Fontemaggi G, Sacchi A, Blandino G. (2007). Mutant p53: an oncogenic transcription factor. Oncogene (this issue).
44. Tsutsumi-Ishii Y, Tadokoro K, Hanaoka F, Tsuchida N. (1995). Response of heat shock element within the human HSP70 promoter to mutated p53 genes. Cell Growth Differ 6: 1-8.
45. Walter K, Warnecke G, Bowater R, Deppert W, Kim EL. (2005). Tumor suppressor p53 binds with high affinity to CTG-CAG trinucleotide repeats and induces topological alterations in mismatched duplexes. J Biol Chem 280: 42497-42507.
46. Wang YH, Griffith J. (1995). Expanded CTG triplet blocks from the myotonic dystrophy gene create the strongest known natural nucleosome positioning elements. Genomics 25: 570-573.
47. Weißker S, Mu¨ller B, Homfeld A, Deppert W. (1992). Specific and complex interactions of murine p53 with DNA. Oncogene 7: 1921-1932.
48. Yang X, Pater A, Tang SC. (1999). Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants. Oncogene 18: 4546-4553.
49. Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, Goncharov TM et al. (2003). Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22: 5667-5676.